Susan Ashwell
About
In The Last Decade
Susan Ashwell
18 papers receiving 891 citations
Peers
Comparison fields: 5 of 77
- Molecular Biology 705
- Oncology 426
- Cell Biology 130
- Cancer Research 128
- Computational Theory and Mathematics 89
Countries citing papers authored by Susan Ashwell
This map shows the geographic impact of Susan Ashwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Ashwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Ashwell more than expected).
Fields of papers citing papers by Susan Ashwell
This network shows the impact of papers produced by Susan Ashwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Ashwell. The network helps show where Susan Ashwell may publish in the future.
Co-authorship network of co-authors of Susan Ashwell
This figure shows the co-authorship network connecting the top 25 collaborators of Susan Ashwell. A scholar is included among the top collaborators of Susan Ashwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Ashwell. Susan Ashwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 111 | |
| 2 | 19 | |
| 3 | 1 | |
| 4 | 26 | |
| 5 | 36 | |
| 6 | 333 | |
| 7 | 57 | |
| 8 | 129 | |
| 9 | Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases | 3 |
| 10 | Structure activity and structure property relationships of a novel series of potent inhibitors of Checkpoint kinases | 1 |
| 11 | Inhibitors of checkpoint kinases: from discovery to the clinic. | 45 |
| 12 | 26 | |
| 13 | 6 | |
| 14 | 71 | |
| 15 | 23 | |
| 16 | 8 | |
| 17 | 5 | |
| 18 | 17 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.